WCN26-7441 The Effect of Intravenous Aminophylline on Preventing Acute Kidney Injury in Sick Neonates – A Multicentric Double blinded, Randomised, Placebo-controlled Clinical Trial

Neonatal acute kidney injury (nAKI) poses a significant mortality risk, particularly in lower-income countries where treatment options are limited and expertise in neonatal dialysis is scarce. Aminophylline, a non-selective adenosine receptor antagonist, may attenuate AKI by promoting renal blood flow and natriuresis. Although aminophylline has shown benefit in select neonatal subgroups like asphyxia, its efficacy in other critically ill term neonates at high risk for AKI remains unexplored.